North Carolina’s restrictions on the use of an abortion-inducing drug conflict with regulatory controls imposed on the drug by the US Food and Drug Administration and should be declared invalid, a state-licensed doctor says in a new complaint.
Amy Bryant’s lawsuit, filed Wednesday, asks the US District Court for the Middle District of North Carolina to declare that the state’s limits on using mifepristone are preempted to the extent that they’re inconsistent with regulations issued by the agency under the Food, Drug, and Cosmetic Act’s Risk Evaluation and Mitigation Strategies provisions.
The case comes at a time when anti-abortion activists ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.